| Date Filed | Type | Description |
| 08/11/2023 |
SC 13D
| Farallon Capital Partners, L.P. reports a 9.9% stake in Chinook Therapeutics, Inc. |
| 08/10/2023 |
SC 13G
| Farallon Capital Partners, L.P. reports a 9.9% stake in Forte Biosciences, Inc. |
| 06/16/2023 |
SC 13D/A
| Farallon Capital Partners, L.P. reports a 2.6% stake in Cazoo Group Ltd |
| 06/02/2023 |
SC 13D/A
| Farallon Capital Partners, L.P. reports a 7.9% stake in Exelixis, Inc. |
| 05/16/2023 |
SC 13D/A
| Farallon Capital Partners, L.P. reports a 2.6% stake in Cazoo Group Ltd |
| 05/15/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 05/11/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 05/08/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 05/08/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 05/03/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 05/03/2023 |
DEFC14A
| Form DEFC14A - Definitive proxy statement, contested solicitations: |
| 04/27/2023 |
SC 13D/A
| Farallon Capital Partners, L.P. reports a 2.6% stake in Cazoo Group Ltd |
| 04/25/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 04/24/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 04/21/2023 |
PRRN14A
| Form PRRN14A - Non-management revised preliminary proxy soliciting materials, contested and otherwise: |
| 04/05/2023 |
DFAN14A
| Form DFAN14A - Additional definitive proxy soliciting materials filed by non-management and Rule 14(a)(12) material: |
| 03/27/2023 |
SC 13D/A
| Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] |
| 03/24/2023 |
SC 13D
| Farallon Capital Partners, L.P. reports a 2.5% stake in Cazoo Group Ltd |
| 03/20/2023 |
SC 13D
| Farallon Capital Partners, L.P. reports a 7.2% stake in Exelixis, Inc. |
| 03/10/2023 |
D/A
| Form D/A - Notice of Exempt Offering of Securities: [Amend] |
| 02/14/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 4.8% stake in Beam Therapeutics Inc. |
| 02/09/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 0% stake in Shelter Acquisition Corporation I |
| 02/09/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 9.7% stake in Swiftmerge Acquisition Corp. |
| 02/09/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 10% stake in Protagonist Therapeutics, Inc. |
| 02/07/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 3.4% stake in Better Therapeutics, Inc. |
| 02/07/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 2.3% stake in Clarivate Plc |
| 02/07/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 0.3% stake in Amyris, Inc. |
| 02/06/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/06/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 7.5% stake in Enanta Pharmaceuticals, Inc. |
| 02/03/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 10% stake in Savara Inc. |
| 02/03/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 10% stake in Longboard Pharmaceuticals, Inc. |
| 02/03/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 0% stake in Imago BioSciences, Inc. |
| 02/01/2023 |
SC 13G/A
| Farallon Capital Partners, L.P. reports a 2.1% stake in Generation Bio Co. |
|